PHIA Koninklijke Philips N.V.

Philips to nominate Mrs. Indra Nooyi as member of the Supervisory Board

Philips to nominate Mrs. Indra Nooyi as member of the Supervisory Board



October 26, 2020

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it will propose the appointment of Mrs. Indra Nooyi as a new member of the Supervisory Board to the Annual General Meeting of Shareholders (AGM), which will be held on May 6, 2021.

“We are very pleased to propose Mrs. Indra Nooyi as a new member of Philips’ Supervisory Board,” said Jeroen van der Veer, Chairman of the Supervisory Board of Royal Philips. “She is a proven business leader in the consumer and technology sectors, with a strong track record of delivering sustained profitable growth, while doing business sustainably and responsibly. Her strategic insights will be highly valuable to Philips, as the company embarks on its next growth phase as a health technology leader, with a purpose to improve the health and well-being of people through innovation.”

Mrs. Nooyi (American, 1955) is the former Chair and CEO of PepsiCo, a global food and beverages company with operations in over 180 countries and 2019 sales of USD 67 billion. During her tenure from 2006 till 2019, she was the chief architect of PepsiCo’s ‘Performance with Purpose’ pledge, and successfully delivered sustained growth by making more nutritious products, limiting its environmental footprint, and empowering its associates and people in the communities it serves. Prior to her appointment as CEO, Mrs. Nooyi held various executive leadership positions, including the role of CFO. Before joining PepsiCo in 1994, Mrs. Nooyi held strategy leadership positions at ABB, a leading global technology company, Motorola, a mobile communications pioneer, and the Boston Consulting Group.

For more information about Philips’ Supervisory Board, please follow this  

For further information, please contact:

Steve Klink

Philips Global Press Office

Tel:

E-mail:

Derya Guzel

Philips Investor Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment

EN
26/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips intends to extend maturity of forward purchases of 4 million s...

Philips intends to extend maturity of forward purchases of 4 million shares for long-term incentive plans September 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this . For further information, please contact:Michael FuchsPhil...

 PRESS RELEASE

Philips and Masimo announce innovation partnership to advance access t...

Philips and Masimo announce innovation partnership to advance access to patient monitoring measurement technologies September 11, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (NASDAQ: MASI) today announced that the two companies have renewed their multi-year strategic collaboration, marking a fresh chapter in their long-standing partnership. With a shared commitment to innovation and expanding access to high-quality, connected care, the two companies are taking a bold new approach in accelerating the development and delivery of next-...

 PRESS RELEASE

Philips launches smart telemetry platform for cardiac monitoring that ...

Philips launches smart telemetry platform for cardiac monitoring that provides continuous, enterprise-wide connectivity beyond the bedside September 4, 2025 Empowering clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move Cambridge, Massachusetts – , a global leader in health technology, today announced the introduction of an  designed to help address critical challenges in healthcare – including staff shortages and alarm management. A key component of the solution is the next-generation Telemetry M...

 PRESS RELEASE

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, deliver...

Philips launches Transcend Plus for EPIQ CVx and Affiniti CVx, delivering breakthrough image quality and FDA-cleared AI enhancements in cardiovascular ultrasound August 27, 2025  Next-generation 2D and 3D imaging and intelligent automation empower clinicians to make faster, more confident decisions in cardiac care Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the release of Transcend Plus, the next generation its EPIQ CVx and Affiniti CVx cardiovascular ultrasound systems. Transcend Plus delivers major advancements in image qua...

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Philips/Volatile results/HOLD

Philips reported a better-than-expected 2Q25 update. We increase our target price to €23 per share (from €21) but keep our Hold rating. The results are surprisingly volatile in our view with large quarterly fluctuations. We believe valuation is fair relative to peers given its lower growth and margin profile.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch